At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 331–340 of 615 results.
-
Researchers want to see if dietary changes can affect chemotherapy response or quality of life in people newly diagnosed with multiple myeloma. The people in this study are receiving standard induction (initial) chemotherapy with daratumumab or isatuximab, lenalidomide, bortezomib, and dexamethasone (DRVd).
-
Umbilical card blood is rich in healthy, blood-forming cells (stem cells) that are very good at fighting blood cancers. Cord blood transplants (CBT) are a standard treatment for adults with blood cancers who lack a genetically matched stem cell donor. Cord blood is donated by a baby's mother at birth. CBT uses stem cells from cord blood collections to replace cells that have been destroyed by disease or anti-cancer treatment.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
There is not an accepted or usual approach to treat patients 75 years of age or older diagnosed with diffuse large B-cell lymphoma (DLBCL). Doctors are seeking effective but less intensive treatment regimens, with fewer side effects, for these patients. A standard treatment for DLBCL is R-CHOP (a combination of the drugs rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
-
In addition, their cancers have a mutation (change) in the G12C location of the KRAS gene. Olomorasib may help slow or stop the growth of cancers with KRAS G12C mutations. It is taken orally (by mouth).
-
Autologous stem cell transplantation (ASCT) is a treatment in which some of a patient's stem cells are removed before high-dose chemotherapy, then returned to the patient to help re-establish the patient's immune system after chemotherapy. Care for a patient after ASCT usually takes place in a hospital. In this study, researchers want to see if it is feasible to care for a patient at home after ASCT for multiple myeloma. Studies at other institutions suggest that providing care at home after ASCT is safe, increases patient satisfaction, and can lower the risk of infection.
-
Researchers are expanding access to the drug zidesamtinib for people with advanced solid tumors. The people in this study have non-small cell lung cancer (NSCLC) or another solid tumor with a fusion (change) in the ROS1 gene. This fusion can cause cancer cells to multiply and spread.
-
The genetic and biochemical makeup of a tumor influences its aggressiveness and the choice of the most appropriate therapy. The purpose of this research study is to determine the genetic and biochemical makeup of neuroblastic tumors, including neuroblastoma, ganglioneuroblastoma, ganglioneuroma, and paraganglioma. These research studies will include analysis of substances called markers that exist on the surface of cancer cells; cytogenetic studies; the identification of genes related to the development of these cancers and to tumor growth; and studies of tumor growth in test tubes. Patients' blood and bone marrow will also be tested for the presence of tumor cells or leukemia cells.
-
Casdozokitug blocks an immune system protein called IL-27. By binding to and blocking IL-27, casdozokitug may help immune cells fight cancer. Toripalimab also helps the immune system fight cancer. Bevacizumab prevents the growth of new blood vessels that feed the cancer. All three drugs are given intravenously (by vein).
-
Germ cell tumors (GCTs) include ovarian teratomas and testicular cancers. The standard treatment for "low-risk" GCTs includes complete removal by surgery followed by chemotherapy with cisplatin, bleomycin, and etoposide, unless the patient is a young child, in which case careful observation may be adequate. GCTs are considered "standard risk" if the patient is under age 25 at diagnosis, the tumor was not completely removed during surgery or has spread to other parts of the body, or proteins in the blood called tumor markers are elevated. The standard treatment for standard-risk GCTs includes chemotherapy with cisplatin, bleomycin, and etoposide followed by surgery, followed by more chemotherapy if needed.